Product Description
Allobarbital (5,5-diallylbarbituric acid) is a medium to long-acting barbiturate. It is under international control according to the UN Convention on Psychotropic Substances (Schedule IV). It is used as a sedative and hypnotic and in combination with acetaminophen and codeine as an analgesic. Allobarbital exerts anticonvulsive activity through GABA-ergic mechanisms. (Sourced from: https://drugs.ncats.io/drug/8NT43GG2HA)
Mechanisms of Action: GABA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Portugal | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12625001037493 |
ACTRN12625001037493 | N/A |
Not yet recruiting |
Stuttering |
2026-05-04 |
2025-10-29 |
Treatments |
|
NCT06476483 |
NCT06476483 | N/A |
Enrolling by invitation |
Acute Respiratory Distress Syndrome |
2025-01-30 |
2025-01-30 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06346496 |
H23133 | N/A |
Completed |
Depressive Disorder |
2023-12-18 |
2024-04-10 |
Primary Endpoints |
|
NCT05654545 |
N22.013 METC-LDD | N/A |
Completed |
Smoking Cessation|Tobacco Use Disorder |
2023-04-19 |
2023-05-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04993248 |
20/112-PCV | N/A |
Unknown status |
Skin Diseases, Infectious|Communicable Diseases |
2022-07-01 |
2023-07-04 |
Primary Endpoints|Treatments|Trial Status |
|
NCT04260672 |
2016721LUC3 | N/A |
Completed |
Pediatric Obesity |
2021-12-31 |
2022-04-15 |
Primary Endpoints|Treatments|Trial Status |
|
ACTRN12611000580976 |
CAPICHe Costs to Australian Private Insurance - Coaching Health | N/A |
Completed |
Chronic Obstructive Pulmonary Disease|Pulmonary Heart Disease|Low Back Pain|Chronic Pain|Heart Failure, Chronic|Liver Failure|Coronary Artery Disease |
2012-06-24 |
2024-08-29 |
Treatments |
|
NCT01134458 |
FIMDM_CVD | N/A |
Completed |
Peripheral Vascular Diseases|Ischemic Stroke|Peripheral Arterial Disease |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT00272727 |
NIS-RDK-DUM-2005/1 | N/A |
Completed |
Asthma |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/05/2026 |
News Article |
Kling AI Launches 3.0 Model, Ushering in an Era Where Everyone Can Be a Director |
|
02/05/2026 |
News Article |
Kling AI Launches 3.0 Model, Ushering in an Era Where Everyone Can Be a Director |
|
02/04/2026 |
News Article |
Sylogist Receives Shareholder Requisition |
|
02/03/2026 |
News Article |
Generali Deutschland AG Selects Clearwater Analytics to Modernize and Scale Investment Operations Unit-Linked Fund Business |
|
05/14/2024 |
PubMed |
Knowledge Graphs and Pretrained Language Models Enhanced Representation Learning for Conversational Recommender Systems. |
|
05/12/2024 |
PubMed |
The Impact of a Computer-Based Interactive Informed Consent for Surgery on Decision Conflict. |
|
04/27/2024 |
PubMed |
Bioinformatics-based analysis of the dialog between COVID-19 and RSA. |